Iteos Therapeutics, Inc. ( (ITOS) ) has released its Q3 earnings. Here is a breakdown of the information Iteos Therapeutics, Inc. presented to ...

DelveInsight's 'Multiple Sclerosis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline multiple ...

Third quarter results highlight strong operational performance across key value drivers: YUPELRI® (revefenacin) net sales of $62.2 million, recognized by Viatris ...

CNW/ - GSK announced today that Health Canada has approved Ojjaara (momelotinib) for the treatment of splenomegaly and/or ...

GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...

Constellation Energy is preparing to restart what's now called the Crane Clean Energy Center on Three Mile Island to supply ...

The winner will be announced Wednesday evening at The American Lawyer's Industry Awards. These attorneys have been named ...

The Shocking Truth" How did Zantac, once the world's most popular drug for acid reflux and heartburn, turn into a toxic ...

AI-enhanced manufacturing applications are now being deployed around the world as a massive upgrade in efficiency.

Full Year 2024 Guidance: 7% to 9% sales growth, 11% to 13% profit growth. GSK PLC (NYSE:GSK) reported a 9% sales growth and 19% profit growth year-to-date, reflecting strong performance in ...

The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...